Cd138 Cells Multiple Myeloma

Multiple myeloma is the 2nd most common blood cancer in adults with a median survival time of 5 years despite high dose chemotherapy and bone marrow transplantation interventions.

Cd138 cells multiple myeloma.

A 69 year old man with a history of cd138 plasma cell myeloma pcm who received chemotherapy regimens and stem cell transplant presented for bone marrow biopsy which revealed sheets of atypical plasma cells with abundant amphophilic cytoplasm occasional binucleation and distinct perinuclear hof panels a b. Original magnification 100 wright giemsa stain a and 40 hematoxylin and. Multiple myeloma mm is a b cell neoplasia characterized by the clonal expansion of malignant plasma cells in the bone marrow. Multiple myeloma mm is a plasma cell malignancy and the second most common hematological neoplasm in adults comprising 1 8 of all cancers.

However decreased expression of cd138 is frequently observed in plasma cells of myeloma patients although the clinical significance of this is unclear. During normal b cell development cells acquire expression of cd138 also known as syndecan 1 sdc1 a marker highly specific for terminally differentiated normal plasma cells cd138 is a heparin sulphate proteoglycan that controls tumor cell. Multiple myeloma research isolation of cd138 cells the leading automated method for purification of cd138 cells from whole bone marrow samples cells are a prerequisite to heighten the sensitivity for multiple myeloma research what is multiple myeloma multiple myeloma mm is a hematological disorder of plasma cells in the bone marrow. Syndecan 1 or cd138 is a heparan sulfate coated glycoprotein which is highly expressed on the surface of plasma cells and myeloma cells important for adhesion and.

Cd138 expression is a hallmark of plasma cells and multiple myeloma cells. Multiple myeloma is a form of cancer caused by b cell neoplasia that results in dysregulated production and clonal expansion of malignant plasma cells cells that express cd138 syndecan 1 and are involved in the production of antibodies during an immune response. However as a result of treatment with bortezomib one of the most widely used therapeutic agents cd138 might be negative or underexpressed which makes this marker unsuitable for detection of residual plasma cells. Mm is a genetically complex highly heterogeneous malignancy with significant inter and intra patient clonal variability.

Stromal reactivity was noted in 7 multiple myeloma cases. The standard diagnosis of multiple myeloma by flow cytometry is based on selection of population of cd38 cd138 cells. In 91 bone marrow biopsies cd138 reactivity was observed for nonneoplastic plasma cells neoplastic plasma cells in multiple myeloma cases 43 43 and the plasmacytic component in lymphoplasmacytic lymphoma cases 4 4. With an annual incidence of 30 770 cases in the united states mm has a high mortality rate leading to 12 770 deaths per year.

The purified cd138 cells are well suited for further flow cytometry functional or molecular analysis.